科研动态PubMed 摘要待译

GLP-1-based therapies for reduction of heart failure and cardiovascular outcomes: A systematic review and meta-analysis of randomized controlled trials.

PubMed 学科轮询 · 2026-01-01

完整摘要 · 中文译文

背景:基于胰高血糖素样肽-1(GLP-1)的疗法在2型糖尿病(T2DM)患者中已显示出超越血糖控制的心血管获益。然而,其对各项心血管及心力衰竭结局影响的程度和一致性仍未完全明确。本系统综述与荟萃分析评估了基于GLP-1的疗法对心血管死亡、心力衰竭住院、不稳定型心绞痛住院、非致死性心肌梗死(MI)及非致死性卒中的影响。 方法:我们检索了MEDLINE(通过PubMed)和Cochrane对照试验中心注册库(CENTRAL),纳入评估基于GLP-1的疗法用于伴或不伴T2DM成人的随机对照试验。两名评价者独立筛选研究、提取数据,并使用Cochrane偏倚风险2工具评估偏倚风险。采用随机效应荟萃分析计算各预设结局的合并风险比(RR)及95%置信区间(CI)。 结果:共纳入11项随机对照试验,包含81,948名参与者,所有研究均判定为低偏倚风险。与安慰剂相比,基于GLP-1的疗法显著降低心血管死亡(RR:0.85,95% CI:0.79-0.91)、心力衰竭住院(RR:0.90,95% CI:0.83-0.97)、非致死性MI(RR:0.87,95% CI:0.79-0.96)及非致死性卒中(RR:0.88,95% CI:0.81-0.97)。基于GLP-1的疗法与安慰剂相比,在不稳定型心绞痛方面未达到具有统计学意义的降低。然而,存在显著的异 观察到研究间异质性,提示所报告的治疗效应存在变异性。大多数结局的异质性较低,尽管非致死性心肌梗死(MI)观察到中度异质性(I² = 56%),不稳定型心绞痛住院观察到显著异质性(I² = 83%)。对于非致死性MI,正式分析未显示小样本研究效应的证据。 结论:基于GLP-1的治疗与心血管死亡率、非致死性MI、非致死性卒中及心力衰竭住院的显著降低相关。这些发现支持基于GLP-1的治疗在2型糖尿病(T2DM)且心血管风险升高患者中的心血管获益,而未观察到因不稳定型心绞痛住院的显著获益。

完整摘要 · 英文原文

BACKGROUND: Glucagon-like peptide-1 (GLP-1) based therapies have demonstrated cardiovascular benefits beyond glycemic control in patients with type 2 diabetes mellitus (T2DM). However, the magnitude and consistency of their effects across individual cardiovascular and heart failure outcomes remain incompletely defined. This systematic review and meta-analysis evaluated the effects of GLP-1-based therapies on cardiovascular mortality, hospitalization for heart failure, hospitalization for unstable angina, nonfatal myocardial infarction (MI), and nonfatal stroke. METHODS: We searched MEDLINE (via PubMed) and the Cochrane Central Register of Controlled Trials (CENTRAL) for randomized controlled trials evaluating GLP-1-based therapies in adults with or without T2DM. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2 tool. Random-effects meta-analyses were performed to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs) for each prespecified outcome. RESULTS: Eleven randomized controlled trials comprising 81,948 participants were included, and all studies were judged to be at low risk of bias. GLP-1-based therapy significantly reduced cardiovascular mortality (RR: 0.85, 95% CI: 0.79-0.91), hospitalization for heart failure (RR: 0.90, 95% CI: 0.83-0.97), nonfatal MI (RR: 0.87, 95% CI: 0.79-0.96), and nonfatal stroke (RR: 0.88, 95% CI: 0.81-0.97). GLP-1-based therapy was not associated with a statistically significant reduction in unstable angina compared with placebo. However, substantial between-study heterogeneity was observed, indicating variability in the reported treatment effects. Heterogeneity was low for most outcomes, although moderate heterogeneity was observed for nonfatal MI (I² = 56%) and substantial heterogeneity for hospitalization for unstable angina (I² = 83%). For nonfatal MI, formal analyses showed no evidence of small-study effects. CONCLUSION: GLP-1-based therapies were associated with significant reductions in cardiovascular mortality, nonfatal MI, nonfatal stroke, and hospitalization for heart failure. These findings support the cardiovascular benefits of GLP-1-based therapies in patients with T2DM and elevated cardiovascular risk, while no significant benefit was observed for hospitalization because of unstable angina.

摘要 待译

BACKGROUND: Glucagon-like peptide-1 (GLP-1) based therapies have demonstrated cardiovascular benefits beyond glycemic control in patients with type 2 diabetes mellitus (T2DM). However, the magnitude and consistency of their effects across individual cardiovascular and heart failure outcomes remain incompletely defined. This systematic review and meta-analysis evaluated the effects of GLP-1-based therapies on cardiovascular mortality, hospitalization for heart failure, hospitalization for unstable angina, nonfatal myocardial infarction (MI), and nonfatal stroke.…

English
GLP-1-based therapies for reduction of heart failure and cardiovascular outcomes: A systematic review and meta-analysis of randomized controlled trials.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界